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Abstract
Background—Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a
common cause of rapidly progressive glomerulonephritis resulting in end-stage renal disease
(ESRD). The optimal timing of kidney transplantation (KTX) for ESRD as a result of AAV and
the risk of AAV relapse after KTX are not well defined. We report our experience with AAV
patients who underwent KTX at our institutions between 1996 and 2010. Median follow-up was
64 months.
Methods—Retrospective multicenter cohort study.
Results—Eighty-five patients (45 men/40 women; mean age 49 years) received a KTX for
ESRD secondary to microscopic polyangiitis (n=43) or Wegener’s granulomatosis (n=42).
Twenty-four patients underwent preemptive KTX and 69 received a living-donor KTX. All
patients were in remission at the time of KTX. Fifty-eight patients received induction therapy. In
64 patients, maintenance immunosuppression was with prednisone, mycophenolate mofetil, and
tacrolimus. At the time of KTX, 29 patients were ANCA-positive. The vasculitis relapse rate was
0.02 per patient-years and was not influenced by disease category, ANCA subtype, or remission
duration before KTX. There were 23 rejection episodes in 13 patients with seven graft losses.
Median serum creatinine at 1 year was 1.3 mg/dL in 75 patients with more than 1 year follow-up
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and 1.4 mg/dL at last follow-up. The graft and patient survival rates were 100% at 1 year, 97.9%
and 93.4% at 5 years, and 79.0% and 67.4% at 10 years, respectively.
Conclusions—KTX is a safe and an effective option for treating ESRD secondary to AAV.
Relapses are rare with current immunosuppression.
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Pauci-immune crescentic glomerulonephritis remains the most common cause of rapidly
progressive renal failure (1). The majority of cases are associated with the presence of
circulating antineutrophil cytoplasmic antibodies (ANCA) (2). The two major subtypes of
ANCA-associated vasculitis (AAV) are Wegener’s granulomatosis (WG) and microscopic
polyangiitis (MPA). Notwithstanding the advances in diagnosis and treatment of AAV, 20%
to 40% of patients developed end-stage renal disease (ESRD) (3–6). Kidney transplantation
(KTX) has been shown to improve survival and quality of life among patients with ESRD,
and several studies have demonstrated that KTX offers a survival benefit compared with
maintenance dialysis (7, 8). Transplanted AAV patients also have lower vasculitis relapse
rates compared with those who remain on dialysis (6, 9–12). A mean 10-year graft survival
of 65.4% has been reported for patients with WG, which compares favorably with graft
survival observed in other nonsystemic inflammatory conditions (13); however, as many as
50% of cases have been said to suffer a vasculitis relapse after KTX, and this may adversely
affect allograft outcome (3, 4, 14–21). A pooled analysis of 127 patients reported in 1999
indicated that AAV recurred in 17.3% of patients after KTX (22). The majority of these
patients (65%) received cyclosporine. In contrast, a much lower vasculitis relapse rate was
observed in two single-center series published in recent years on AAV patients using
modern immunosuppressive agents (23, 24). Gera et al. (23), in a single-center series of 35
transplant recipients with diagnoses of AAV reported nonrenal relapses in three patients
(8.6%). No clear risk factor to relapse emerged and no detrimental effect to renal function
was found. In addition, another single-center analysis of 17 patients with AAV who
underwent KTX identified relapses in three patients over a median follow-up of 37 months
(24). More recently, Little et al. (25) reported relapses in only 5 of 107 transplanted AAV
patients (4.7%). Overall graft survival was 70% after 10 years. ANCA status per se was not
significantly associated with graft failure, and the strongest predictor of death was
transplantation less than 1 year from the time of vasculitis remission (25). This study
included patients transplanted over a 20-year period and did not have details of
posttransplant immunosuppression.
These discrepancies and the paucity of information regarding long-term transplant outcomes
for AAV in the modern era of immunosuppression led us to extend our previous
observations by conducting this multicenter study to address questions regarding the
influence of waiting period after remission is achieved before KTX, influence of disease
subtypes, ANCA status at the time of KTX, and the effect antirejection regimen on graft
outcome and vasculitis relapse rate in this patient population.
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A total of 85 patients received KTX for ESRD secondary to AAV. Forty-two patients had
WG and 43 patients had MPA. The clinical characteristics of the cohort are listed in Table 1.
The mean age at transplantation was 49±18.2 years. Sixty-nine patients received a KTX
from a living-related donor. Twenty-four patients were transplanted preemptively. The
remaining 61 patients spent a median of 17.5 (range, 1–120) months on dialysis before
receiving a KTX. All patients were in clinical remission at the time of KTX, with 57 of 85
patients (67.0%) in remission for more than 12 months. At the time of transplantation,
ANCA testing by immunofluorescence was carried out in 75 of the 85 patients and was
positive in 29 of the 75 patients (38.7%).
Transplant Immunosuppression
Fifty-eight patients received induction therapy with the majority of them receiving
antithymocyte globulin (Table 2). Sixty-four patients (75% of total) received maintenance
immunosuppression with prednisone, mycophenolate mofetil, and tacrolimus. There were no
differences in the dose of mycophenolate mofetil used or target tacrolimus drug levels in
patients who were ANCA positive compared with patients who were ANCA negative at the
time of transplant. Eighty-one patients were maintained on steroids and the remaining four
were on a steroid avoidance protocol.
Transplant Outcomes
Clinical outcomes were followed-up until patient death, graft loss with return to dialysis, or
most recent documentation of graft status. The median post-KTX follow-up was 64 (range,
3–165) months. There were 23 biopsy-proven rejection episodes in 13 patients. Six patients
developed biopsy-proven polyomavirus (BK)-associated nephropathy. The median serum
creatinine at 1 year was 1.3 mg/dL in the 75 patients who had more than 1 year of follow-up.
The median serum creatinine at last follow-up was 1.4 mg/dL. There was no difference in
the median serum creatinine at the last follow-up between patients with WG and MPA (1.4
vs. 1.3, P=0.09). Similarly, there was no difference in median serum creatinine at the last
follow-up of patients who were ANCA positive at the time of transplant compared with
those who were ANCA negative (1.4 vs. 1.3, P=0.31). There were seven graft losses in this
cohort. In three patients, graft loss was due to noncompliance with immunosuppression,
three patients developed chronic allograft nephropathy and one patient developed renal cell
carcinoma in the KTX.
Kaplan-Meier plots for overall graft survival and death-censored graft survival are presented
in Figure 1. As shown, a total of 11 patient deaths occurred between 25 and 152 months
after KTX. Eight patients had functioning KTX at the time of death, whereas three patients
lost KTX before their death. An additional four grafts were lost between 70 and 84 months
post-KTX. Deaths were due to cancer (n=3), sepsis (n=1), amyloidosis (n=1), intracranial
hemorrhage (n=2), and unexplained sudden death (n=4). Overall graft survival at 5 years
was 97.9% with death-censored graft survival of 93.4% at this time point.
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Vasculitis Outcomes and Risk of Relapse
At the time of transplant, 75 patients had been tested for ANCA. Twenty-nine (38.7%)
patients were ANCA positive and the rest were ANCA negative. A total of eight relapses
occurred in seven patients (5 with WG and 2 with MPA; Table 3). The vasculitis relapse rate
was 0.02 per patient year. All flares occurred in the presence of detectable circulating
ANCA. Two patients with MPA, one ANCA positive and one unknown, and both patients in
remission for more than 1 year before KTX developed a necrotizing glomerulonephritis
within 3 months of KTX. One patient responded to a 3-month course of cyclophosphamide,
and another patient responded to a change in immunosuppression from azathioprine to
mycophenolate mofetil. One patient with WG developed two episodes of a pulmonary-renal
syndrome 45 and 55 months after KTX; the latter occurred in the setting of non-compliance
with his immunosuppression and resulted in graft loss. A second patient with WG developed
lung hemorrhage followed by pneumonia and methicillin resistant staphylococcus aureus
(MRSA) sepsis 44 months after KTX; this patient died of sepsis 2 months later. The
symptomatic presentation of the remaining cases of relapse in WG involved upper
respiratory tract alone (n=1); multiple joints (n=1); and upper respiratory tract, joints, and
skin (n=1). None of the remaining patients experienced renal or extra renal relapse of
vasculitis after KTX after a median observation period of 64 months. Four of the seven
patients who experienced a relapse were ANCA positive at the time of KTX, one patient
was ANCA negative, and in two patients, the ANCA status at the time of KTX was
unknown. We found that being ANCA positive at the time of the KTX was associated with
an increased odds of developing a vasculitis relapse (95% confidence interval 0.998–
144.932, P=0.05). However, this finding is limited by the fact that in two patients their
ANCA status was unknown and could not be included in the analysis. There was no
correlation between relapse and ANCA type (p-ANCA vs. c-ANCA P=0.7). There was no
statistically significant difference regarding the time on dialysis before KTX between
relapsers and nonrelapsers. There was no significant difference in relapse rate between KTX
patients who had been in remission for less than 12 months and those who had been in
remission for a longer period. Although patients with WG seemed to have a higher relapse
rate (11.9%) when compared with patients with MPA (4.7%), this difference did not reach
statistical significance (P=0.6). There was also no difference in relapse rate between the
three centers. There was no significant difference in use of induction therapy (P=0.4) and
use of mycophenolate mofetil (P=0.7) in patients who experienced a relapse versus patients
who did not experience a relapse.
DISCUSSION
This multicenter study reports allograft outcomes and vasculitis relapse rates in 85 AAV
patients who underwent KTX in the era of modern immunosuppression. Of the 85 patients
reported in this study, 52 have been reported in earlier studies as single-center experiences
(23, 24). We have now extended this observation to an additional 33 patients and reported
outcomes with a longer follow-up on the 52 patients reported in our earlier studies. This
study represents the largest and most uniformed series of AAV patients who underwent
KTX in the era of modern immunosuppression, and it is the one with the longest follow-up.
We sought to address questions regarding the influence of remission time before the KTX,
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influence of disease subtypes and ANCA status at the time of KTX on vasculitis relapse, the
effect anti-rejection regimen on graft outcome, and vasculitis relapse rate and the safety of
immunosuppression in this patient population. Overall graft survival was 120 months. There
was no significant difference in vasculitis relapse rate among patients who were transplanted
less than 3 months of entering into clinical remission compared with those who remained in
remission longer (P=0.2). We found that ANCA positivity at the time of transplantation
tended to be associated with an increased risk for a vasculitis relapse, but these data need to
be taken with caution in view of the small number of patients, the fact that in two patients,
ANCA status at the time of KTX was unknown, and in one patient, the relapse occurred in
the setting of noncompliance with medication. More important, ANCA positivity per se at
the time of transplantation was not associated with adverse graft survival. There was no
difference in median serum creatinine at the last follow-up between different disease
categories or ANCA subtype.
Our results confirm earlier reports demonstrating that KTX is an excellent option for the
treatment of patients with ESRD secondary to AAV with lower death rate and lower
vasculitis relapse rates compared with AAV patients on dialysis. Lionaki et al. (26) reported
59 deaths among 93 AAV patients on dialysis over a median follow-up time of 63 months.
The corresponding mortality rate was 0.31 deaths per person per year. Data from the
Collaborative Transplant Study show that patients with AAV who received a deceased
donor KTX had a 10-year patient survival rate of 80% (13). Similarly, in a case series of 22
AAV patients who underwent KTX, Allen et al. (3) reported post-KTX patient survival of
100% and 85% at 1 and 5 years, respectively, with graft survival of 86% and 69%,
respectively. In our previous single-center analysis of KTX in patients with AAV using
modern immunosuppressive agents, the overall and death-censored graft survivals were 94%
and 100%, respectively, 5 years post-transplantation (23). The overall and death-censored
graft survival at 5 years in this cohort was 93.4% and 97.9%, respectively.
Transplanted AAV patients experience lower vasculitis relapse rate compared with AAV
patients on dialysis and AAV patients with chronic kidney disease who are not on dialysis.
Allen et al. (3) reported a vasculitis relapse rate of 0.09 relapses per patient per year in 37
patients with AAV on dialysis compared with a vasculitis relapse rate of 0.02 per patient per
year in 22 transplanted AAV patients. Lionaki et al. (26) reported a vasculitis relapse rate of
0.08 episodes per person year in 93 patients with AAV on dialysis and a vasculitis relapse
rate of 0.16 episodes per person year in 359 patients in AAV patients with renal involvement
who had not reached ESRD. There has been, however, great variability regarding relapse
rates in AAV patients after KTX (3, 14–20). A pooled analysis by Nachman et al. (22),
reported an overall relapse rate of 17%, with an average time from KTX to relapse of 31
months. On the other hand, Schmitt et al. (19) reported a vasculitis relapse rate of 0.1
episodes per patient per year in 20 patients with WG with a mean follow-up of 48 months.
Similarly, Haubitz et al. (16) reported a vasculitis relapse rate of 0.06 per patient per year. In
a report of nine patients with AAV and KTX, the vasculitis relapse rate was 0.04 per patient
per year (27). The reports mentioned above were based on data from patients mainly treated
with prednisone, cyclosporine, and azathioprine for maintenance immunosuppression. More
recently, however, a relapse rate of 0.005 per patient per year was reported in 17 patients
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with AAV whose maintenance KTX immunosuppression was based on the use of tacrolimus
and mycophenolate mofetil (24). Moreover, Gera et al. (23) reported a relapse rate of 0.02
per patient per year in 35 AAV patients undergoing KTX using modern immunosuppressive
agents. Our data confirm and strengthen prior observations that, with current
immunosuppression therapy, vasculitis relapse rate after KTX is low and does not affect
graft survival.
Because of the risk of recurrent disease in the setting of active disease, it is generally
recommended to wait until clinical remission is achieved before proceeding to KTX. The
optimal duration of clinical remission required before transplantation is not clear. Little et al.
showed that KTX shortly after induction of remission was the strongest predictor of
mortality after transplantation. However, in our study, the vasculitis relapse rate was not
influenced by duration of remission. In contrast to anti-glomerular basement membrane
(GBM) disease where persisting anti-GBM antibodies are associated with a higher
recurrence rate, evidence is accumulating that the presence of positive ANCA should not
preclude transplantation in patients who are clinically in remission. C-ANCA was detectable
in 8 of 12 WG patients at the time of transplantation in the study by Schmitt et al. (19) and
in seven of the eight patients in a case series by Rostaing et al. (18). Only one of the patients
in the latter group relapsed; four others remained ANCA positive during follow-up but
remained in remission. Similarly, Deegens et al. (28) studied the outcome of KTX in 33
patients with AAV transplanted between 1968 and 2000 under varying immunosuppressive
regimens. ANCA testing was carried out in 18 patients around the time of transplantation,
and positive ANCA by immunofluorescence was found in eight patients (8 of the 18; 44%).
Only one patient (3%) with WG developed an extra renal relapse, with none of the patients
developing a renal relapse. In a pooled analysis of recurrent AAV after renal transplant in 33
patients, there was no significant difference in the relapse rate between those with or without
detectable ANCA titers at the time of transplantation (22). There was also no difference in
the rate of relapse after KTX based on ANCA pattern or antigen specificity. In our previous
study (23), there was a trend toward higher relapse rate among patients who had a positive
ANCA test before KTX (13% vs. 5%) but the difference was not statistically significant and
relapses among both groups were infrequent and clinically manageable. A similarly trend
was observed in the current study (13.8% vs. 2.2%), but again this needs to be taken with
caution because of the reason discussed above. Thus, ANCA status at the time of transplant
should not preclude KTX.
Differences in renal outcomes and risk of relapse have been reported between patients with
MPA versus WG. In a single-center case series, the median serum creatinine at the time of
last follow-up was higher among patients with WG than MPA (1.3 vs. 1.0 mg/dL) (24). In
contrast to this, we did not find a difference in median serum creatinine at last follow-up
when patients with WG were compared with MPA (1.2 vs. 1.3 mg/dL, P=0.09).
The present cohort represents the largest experience with KTX for AAV and is specifically
relevant to current practice trends in KTX. The study is subject to the limitations inherent to
a retrospective analysis. The data were pooled from three centers. However, there were no
significant differences in immunosuppressive drug use, allograft function, or vasculitis
relapse rates between the three centers. Vasculitis activity at the time of KTX was defined
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based on clinical criteria and did not use standardized Birmingham Vasculitis Assessment
Score (WG). Nonetheless, our results showed that with current immunosuppression the risk
of recurrence of vasculitis post-KTX is low and supports the conclusion that KTX is the
treatment of choice for patients with ESRD due to AAV who are in clinical remission at the
time of transplantation regardless of ANCA status.
MATERIALS AND METHODS
Study Population
The study population included all KTX recipients from 1996 to 2010 who had AAV listed as
the primary cause of ESRD and were followed-up at Mayo Clinic, Rochester, Minnesota;
Johns Hopkins Hospital, Baltimore, Maryland; and University of Chapel Hill, North
Carolina. The study protocol was approved by the institutional review board at each
institution. For the purposes of this study, the diagnosis of systemic vasculitis required
documentation of the following: (a) a diagnosis of vasculitis proven by biopsy and (b)
positive ANCA testing. Patients were classified as WG or MPA as defined by the Chapel
Hill Consensus Conference (2, 29).
Data Acquisition
Clinical, laboratory, and histologic data were abstracted from review of medical records of
all cases meeting study entry criteria. Data regarding patient demographics, donor source,
prior KTX, disease subtype, ANCA type and status at time of transplant, duration of dialysis
pretransplant when applicable, duration of remission before transplant, presence of delayed
graft function, data on induction therapy, maintenance immunosuppressive regimen, serum
creatinine at 1 year and last follow-up, episodes of allograft rejection and details of
treatment of allograft rejection, occurrence of vasculitis relapse posttransplant, relapse type
and treatment of relapse, and occurrence of graft loss. Overall and death-censored graft
survival rates were examined by Kaplan-Meier survival curves. Data are presented as means
(±standard deviation) or medians (range) when appropriated. All statistics were performed
using JMP software, version 8.0 (SAS Institute Inc., Cary, NC).
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Kaplan-Meier curves are shown for overall kidney transplant survival (graft survival) and
death-censored kidney transplant survival among 85 recipients with ESRD due to AAV.
ESRD, end-stage renal disease; AAV, antineutrophil cytoplasmic antibody-associated
vasculitis.
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TABLE 1
Baseline characteristics of KTX recipients with native kidney failure due to AAV
Patient number 85
Form of AAV (WG:MPA) 42:43
History of prior KTX, n (%) 8 (9.4)
ANCA-positive at time of KTX, n (%) 29 of 75 (38.7)
Age at transplant (mean±SD, yr) 49±18.2
Gender (M:F) 45:40
Donor source, n (%)
 LRD 54 (63.5)
 LURD 15 (17.6)
 DD 16 (18.8)
Preemptive KTX, n (%) 24 (28.2)
Time on dialysis, median (range), mo 17.5 (1–120)
Time between last AAV activity and KTX, median (range), mo 12 (4–120)
ANCA, antineutrophil cytoplasmic antibody; AAV, ANCA-associated vasculitis; DD, deceased donor; LRD, living-related donor; LURD, living-
unrelated donor; MPA, microscopic polyangiitis; WG, Wegener’s granulomatosis; KTX, kidney transplantation; SD, standard deviation.
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TABLE 2
Kidney transplant-related immunosuppression and posttransplant outcomes
n (%)
Induction immunosuppression
 None 27 (31.8)
 IL-2 receptor antagonist 14 (16.5)
 Antithymocyte globulin 41 (48.2)
 Anti-CD52 (alemtuzumab) 3 (3.5)
Primary oral immunosuppressant
 TAC/MMF/P 64 (75.0)
 CsA/MMF/P 7 (8.2)
 CsA/SRL/P 2 (2.4)
 SRL/MMF/P 2 (2.4)
 TAC/AZA/P 2 (2.4)
 TAC/SRL/P 1 (1.2)
 TAC/MMF 4 (4.7)
 TAC/P 2 (2.4)
 CsA/P 1 (1.2)
Follow-up (mean±SD, yr) 5.4 (3.4)
Acute rejection, n (%) 13 (15.3)
Polyomavirus (BK)-associated nephropathy 6 (7.1)
SCr at 1 yr post-KTX, median (range), mg/dL 1.3 (0.8–2.4)
Clinical relapse of AAV
 Total group 7/85 (8.2)
 WG group 5/42 (11.9)
 MPA group 2/39 (5.1)
 ANCA-positive at time of KTX 4/29 (13.8)
 ANCA-negative at time of KTX 1/46 (2.2)
 ANCA-unknown at time of KTX 2/10 (20.0)
AZA, azathioprine; CsA, cyclosporine; MMF, mycophenolate mofetil; MPA, microscopic polyangiitis; SRL, sirolimus; TAC, tacrolimus; WG,
Wegener’s granulomatosis; ANCA, antineutrophil cytoplasmic antibody; KTX, kidney transplantation; IL, interleukin; AAV, ANCA-associated
vasculitis.
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